OncLive TV

Toni K. Choueiri, MD, discusses the potential clinical effects of data from the phase 3 LITESPARK-022 study.

Rami Komrokji, MD, discusses strategies and barriers for utilizing current risk-stratification tools in myelodysplastic syndromes.

Shubham Pant, MD, MBBS, discusses data from the phase 3 BREAKWATER trial supporting upfront targeted therapy in BRAF V600E–mutant mCRC.

Toni K. Choueiri, MD, discusses safety data from the phase 3 LITESPARK-022 study in ccRCC.

Key experts across oncology specialties share how they prioritize patient safety in their practices related to AE awareness and mitigation strategies.

Laura J. Esserman, MD, MBA, discusses the potential utility of risk-based screening for breast cancer.

Javid Moslehi, MD, discusses the role of the cardiologist in the setting of breast cancer management to facilitate optimal cancer management.

Matthew D. Galsky, MD, discusses data from the phase 3 KEYNOTE-B15 trial in patients with MIBC.

Toni K. Choueiri, MD, discusses prior data that led to the initiation of the LITESPARK-022 trial in ccRCC.

Javid Moslehi, MD, highlights current cardiac monitoring protocols associated with breast cancer drugs and ways to refine these protocols in the future.

Laura J. Esserman, MD, MBA, discusses key results from the WISDOM 1.0 breast cancer screening trial.

Javid Moslehi, MD, explains the intersection of cardiovascular health and oncology when optimizing breast cancer treatment decision-making.

Laura J. Esserman, MD, MBA, explains current gaps with breast cancer screening methods.

R. Lor Randall, MD, FACS, discusses results from an analysis of factors associated with local recurrence risk in nonmetastatic Ewing sarcoma.

Vishal Patel, MD, FAAD, FACMS, discusses the importance of multidisciplinary care for patients with locally advanced or unresectable CSCC.

Alexander T. Pearson, MD, PhD, discusses the role of AI for clinical trial design and enrollment.

Matthew D. Galsky, MD, unpacks the design of the phase 3 KEYNOTE-B15 in patients with MIBC.

Rachna T. Shroff, MD, MS, FASCO, discusses how bringing a diversity of perspectives to clinical trial design has moved the needle in pancreatic cancer.

Kevin Kalinsky, MD, MS, FASCO, notes insights from a molecular tumor board discussion about the optimal management of HR-positive metastatic breast cancer.

Meghan R. Flanagan, MD, MPH, noted the nuanced discussions that multidisciplinary tumor boards should have to optimize breast cancer management strategies.

Patricia Jakel, MSN, notes the factors that influence breast cancer care, as exemplified in a discussion at the 43rd Annual Miami Breast Cancer Conference.

Lillian Rodich, MSPAS, MPH, highlights ways that medical oncologists can counsel patients with breast cancer about integrative medicine modalities.

Matthew D. Galsky, MD, discusses the background of the phase 3 KEYNOTE-B15 trial in muscle-invasive bladder cancer.

Daniel J. DeAngelo, MD, PhD, discusses debate points in acute lymphoblastic leukemia care that future research could address.

Vincent Picozzi, MD, discusses how data from the phase 3 PANOVA-3 trial are foundational for the evaluation of Optune Pax with other immunotherapies.

Alexander T. Pearson, MD, PhD, discusses how AI can be used for oncologic drug discovery and development.

Sunandana Chandra, MD, discusses the current systemic treatment landscape for patients with unresectable, locally advanced, or metastatic cutaneous squamous cell carcinoma.

Megan Kruse, MD, emphasizes the importance of observing Triple-Negative Breast Cancer Day through continued disease education and treatment development.

Tycel Phillips, MD, discusses ongoing clinical trials in mantle cell lymphoma and how their data may influence the field.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss how they go about determining which patients are suitable candidates for clinical trials.